| European Case Law Identifier: | ECLI:EP:BA:2015:R000813.20150915 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 15 September 2015 | ||||||||
| Case number: | R 0008/13 | ||||||||
| Petition for review of: | T 1676/08 | ||||||||
| Application number: | 96102992.3 | ||||||||
| IPC class: | A61K 31/485 A61K 9/20 A61P 25/04 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | B | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Controlled release oxycodone compositions | ||||||||
| Applicant name: | The Purdue Pharma Company Mundipharma GmbH Napp Pharmaceutical Holdings Limited Norpharma A/S Mundipharma Pharmaceuticals S.R.L. Mundipharma Laboratories GmbH Mundipharma Pharmaceuticals BV Mundipharma AB Mundipharma AG Mundipharma Farmaceutica LDA Mundipharma Pharmaceuticals SL Mundipharma GesmbH Mundipharma CVA |
||||||||
| Opponent name: | Lannacher Heilmittel Ges.m.b.H. | ||||||||
| Board: | EBA | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Violations of the right to be heard: no. Other procedural defects: no Petition not allowable |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/r130008eu2.html
Date retrieved: 17 May 2021
29 references found.
Click X to load a reference inside the current page, click on the title to open in a new page.EPC Articles
EPC Implementing Rules
Case Law Book: III Amendments
XCLR III J 6.2.3 Suspected partiality of the Chairman of the Enlarged Board of Appeal who at the same time was Vice-President of Directorate-General 3 (VP3)